Drugs / scAAV9/JeT-GAN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02362438 | Apr 2015 → Apr 2026 | giant axonal neuropathy | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | scAAv9/JeT-GAN | “scAAv9/JeT-GAN is a biological gene transfer reagent” NCT02362438 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a self-complementary adeno-associated virus-based gene therapy” PMID 38507752 ↗ Mar 2024 |
| Route | Intrathecal | “scAAV9/JeT-GAN administered intrathecally” NCT02362438 ↗ |
| Target | GAN | “AAV vector carrying a normal copy of the human GAN transgene” PMID 29766026 ↗ Feb 2018 |